Study of AZD2811 + Durvalumab in ES-SCLC

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

February 23, 2021

Primary Completion Date

June 18, 2022

Study Completion Date

December 1, 2025

Conditions
Small-Cell Lung Cancer
Interventions
DRUG

Durvalumab

"IV infusions through induction phase.~IV infusions through maintenance phase until PD or other discontinuation criteria."

DRUG

AZD2811

IV infusions through maintenance phase until PD or other discontinuation criteria.

DRUG

Carboplatin

IV infusions through induction phase if chosen by Investigator.

DRUG

Cisplatin

IV infusions through induction phase if chosen by Investigator.

DRUG

Etoposide

IV infusions through induction phase.

Trial Locations (12)

28644

Research Site, Cheongju-si

41071

Research Site, Seville

46015

Research Site, Valencia

49503

Research Site, Grand Rapids

52727

Research Site, Jinju

85-796

Research Site, Bydgoszcz

10-357

Research Site, Olsztyn

60-693

Research Site, Poznan

03722

Research Site, Seoul

05505

Research Site, Seoul

06351

Research Site, Seoul

06591

Research Site, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY